首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   38150篇
  免费   3525篇
  国内免费   1404篇
耳鼻咽喉   348篇
儿科学   569篇
妇产科学   511篇
基础医学   5543篇
口腔科学   3067篇
临床医学   5388篇
内科学   4743篇
皮肤病学   712篇
神经病学   1889篇
特种医学   1702篇
外国民族医学   8篇
外科学   5510篇
综合类   4770篇
一般理论   1篇
预防医学   1943篇
眼科学   532篇
药学   2330篇
  13篇
中国医学   1160篇
肿瘤学   2340篇
  2023年   616篇
  2022年   713篇
  2021年   1153篇
  2020年   1502篇
  2019年   1461篇
  2018年   1419篇
  2017年   1400篇
  2016年   1358篇
  2015年   1448篇
  2014年   2520篇
  2013年   3164篇
  2012年   2152篇
  2011年   2459篇
  2010年   1894篇
  2009年   1919篇
  2008年   2005篇
  2007年   2022篇
  2006年   1800篇
  2005年   1660篇
  2004年   1411篇
  2003年   1236篇
  2002年   916篇
  2001年   841篇
  2000年   649篇
  1999年   575篇
  1998年   424篇
  1997年   394篇
  1996年   341篇
  1995年   356篇
  1994年   317篇
  1993年   250篇
  1992年   267篇
  1991年   245篇
  1990年   206篇
  1989年   183篇
  1988年   191篇
  1987年   167篇
  1986年   133篇
  1985年   191篇
  1984年   143篇
  1983年   109篇
  1982年   135篇
  1981年   145篇
  1980年   127篇
  1979年   89篇
  1978年   75篇
  1977年   58篇
  1976年   77篇
  1975年   32篇
  1972年   28篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
目的 研究壳三糖在大鼠体内的组织分布及排泄。方法 建立并验证了大鼠组织、尿液和粪便中壳三糖的高效液相色谱-质谱联用(LC-MS/MS)检测方法。大鼠灌胃给药壳三糖35 mg/kg后,分别在0.5、1.5、3 h 摘取组织,0 h - 4 h、4 h - 8 h、8 h - 12 h、12 h - 24 h 、24 h - 36 h、36 – 48 h时间段收集尿液和粪便。用建立的LC-MS/MS方法测定组织、尿液和粪便中的壳三糖含量。结果 组织、尿液和粪便中壳三糖在10 - 10000 ng/mL的浓度范围内线性良好,日内、日间精密度的相对标准偏差(relative standard deviation,RSD )≤14.20%,准确度的相对误差(relative error,RE)为?11.30%~8.33%,提取回收率为85.2% - 97.9%,没有明显的基质效应,在室温放置24 h、反复冻融以及-40℃放置30天的条件下稳定性良好,满足生物样品的检测需求。灌胃给药后,0.5 h就可以在主要组织检测到壳三糖,1.5 h肾脏中壳三糖含量明显升高,3 h未在大脑中检测到壳三糖。48 h后壳三糖在尿液、粪便中的排泄率分别为7.15%、72.80%。结论 壳三糖主要以原型的形式在大鼠体内分布和排泄,壳三糖在大鼠各组织中的分布较为广泛,以肝和肾为主,粪便是壳三糖的主要排泄途径。  相似文献   
3.
ObjectiveTo analyze the effects of electrolysis, through a medium frequency current, associated to aerobic physical activity in the body composition of young women.MethodsThe study was composed of 34 sedentary women (24.35 ± 4.43 years, 71.30 ± 7.08 kg, 1.61 ± 0.06 m, 27.31 ± 1.67 kg/m2) which were evaluated for their anthropometric measures and body composition. The volunteers were randomly assigned to two group: Electrolyphysis plus Aerobic Exercise (gEEA): 17 volunteers were submitted to the application, for 60 min , of the Aussie current, followed by aerobic physical activity (77% of HRmax) on the trampoline for 40 min, through video-lessons of Jump; and Aerobic Exercise group (gEA): 17 volunteers performed only physical activity following the same parameters mentioned above. Each group performed its protocols twice weekly, for 5 weeks, totaling 10 sessions. For the data analysis, measures repeated ANOVA was performed to compare the means of the variables analyzed before and after the treatment protocols using the SPSS - 21.0 software, adopting a p ≤ 0.05.ResultsAlthough gEEA decreased suprailiac skinfold (p = 0.04), abdominal skinfold (p = 0.03) and circumference at umbilical scar (p = 0.02) in an intragroup analysis, these means differences in anthropometric measures were not important between-groups (p > 0.05). Furthermore, there were no effect of treatment on body composition (p > 0.05).ConclusionTo this studied condition, our results suggested that application of medium frequency electrolysis did not enhance the losses on anthropometric measures and body composition.  相似文献   
4.
目的 观察治伤巴布剂对急性软组织损伤(acute soft tissue injury, ASTI)模型p38丝裂原活化蛋白激酶(mitogen-activated protein kinase,MAPK)、丝/苏氨酸蛋白激酶(AKT)信号通路的影响,探讨治伤巴布剂干预ASTI的可能作用机制。方法 将40只雄性SD大鼠按照随机数字表法分为正常对照组、模型对照组、治伤巴布剂组、p38MAPK信号通路抑制剂组、AKT信号通路抑制剂组,每组8只。除正常对照组外,其余四组均予以左侧后肢小腿ASTI造模。造模成功后,治伤巴布剂组于标记部位立即予治伤巴布剂(修剪成1.5x3cm大小)外敷,并用胶布固定;其余四组均予等剂量赋形剂(修剪成1.5×3 cm大小)外敷处理,胶布固定;持续外敷,共持续24 h。p38MAPK信号通路抑制剂组在造模前30 min予腹腔注射p38MAPK信号通路抑制剂SB203580(400 μg/kg/天)1次;AKT信号通路抑制剂组在造模前30 min予腹腔注射AKT信号通路抑制剂perifosine(20 mg/kg/天)1次。分别于0(造模前)、2h、4h、8h、12h、24h测量受伤小腿肌肉处的周长,并计算肌肉肿胀率(muscle swelling rate,MSR)。24 h药物干预结束后,采用颈椎脱臼法处死大鼠。后将左侧后肢小腿损伤中心部位进行取材,分成三份。一部分用于观察组织病理学形态变化;一部分用于逆转录聚合酶链反应(RT-PCR)检测核因子-κB(nuclear factor kappa-B,NF-κB)p65 mRNA、肿瘤坏死因子-α(TNF-α)mRNA、白细胞介素-1β(IL-1β)mRNA表达水平;剩下部分用酶联免疫吸附试验(ELISA)法检测骨骼肌组织TNF-α、IL-1β含量水平及蛋白质免疫印迹(Western-blot)法测定p38MAPK、AKT、NF-κB p65、核因子抑制蛋白α(inhibitor kappa B alpha, IκBα)表达水平。结果 与正常对照组相比,模型对照组MSR显著增加(P<0.01);病理形态学上,骨骼肌组织可见大面积肌细胞排列紊乱,肌细胞变性坏死,间质内可见红细胞聚集及大量炎症细胞浸润;骨骼肌组织TNF-α、IL-1β含量水平显著升高(P<0.01);磷酸化p38MAPK(p-p38)/总p38MAPK(t-p38),磷酸化-AKT(p-AKT)/总-AKT(t-AKT)明显升高(P<0.01),NF-κB p65及NF-κB p65mRNA表达水平明显升高(P<0.01)。与模型对照组相比,治伤巴布剂组MSR在治疗第8 h、12 h、24 h显著下降(P<0.01),且在治疗第24 h,其MSR较p38MAPK、AKT信号通路抑制剂组下降更明显(P<0.05);病理学评分显著下降(P<0.01),且较p38MAPK、AKT信号通路抑制剂组下降更显著(P<0.05);骨骼肌组织TNF-α、IL-1β含量水平明显下降(P<0.01),且较p38MAPK、AKT信号通路抑制剂组更显著(P<0.05);p-p38/t-p38及p-AKT/t-AKT明显下降(P<0.01),NF-κB p65及NF-κB p65 mRNA表达水平显著下降(P<0.01),且较p38MAPK、AKT信号通路抑制剂组在降低NF-κB p65及NF-κB p65 mRNA相对表达值方面更显著(P<0.01)。结论 治伤巴布剂可能同时对p38MAPK、AKT信号通路产生了一定的抑制作用,引起NF-κB活性下调,NF-κB p65蛋白的表达下调,进而引起骨骼肌组织TNF-α、IL-1β炎性细胞因子含量水平下调,减轻ASTI炎症反应,从而改善ASTI。  相似文献   
5.
BackgroundIntraabdominal and retroperitoneal sarcomas (IaRS) are malignant connective tissue tumors. Surgical resection is often the only curative treatment. The primary objective was to report the mid-term outcomes following contemporary treatment protocols and identify prognostic factors.MethodsA retrospective review of consecutive patients (n = 107) with IaRS treated at single center from 2013 until 2018 was conducted. Histological diagnosis, tumor grade, perioperative complications, mortality, and long-time survival were registered and retrieved from patient records. Primary and recurrent tumors were analyzed separately.ResultsA total of 107 patients were identified. Median follow-up time was 3.5 years. Thirty-day mortality was 3.4% and 90-day mortality was 5.6% for all tumors. The major complication rate was 18%. The 5-year estimated survival for primary and recurrent tumors was 55.4% and 48.4%, respectively. Multifocal disease was evident in 32% of the patient cohort, and 58% of patients in the recurrent group. Multivariate analysis for survival revealed a hazard ratio (HR) of 3.1 (95% CI 1.68–8.41) for multifocality, HR 2.9 (95% CI 1.28–6.98) for Clavien-Dindo grade, HR 2.3 (95% CI 1.21–4.31) for tumor grades 2 or 3, and HR 1.002 (95% CI 1.001–1.004) for surgical margins.ConclusionsOur study found overall acceptable morbidity and mortality, and identified prognostic markers for overall survival. Recurrent tumors were not associated with worse survival. Multifocality is associated with a worse overall survival. The prognostic factors identified were; tumor grade, multifocality, intralesional margins and postoperative complications.  相似文献   
6.
ObjectivesPurposeful SDM posits four modes of shared decision making (SDM). The use of each mode depends on the type of problem of care that is being addressed. We sought to identify how current observer-based SDM measures apply to each mode of Purposeful SDM.MethodsFour coders, working independently, evaluated 192 items pertaining to 12 observer-based SDM process measures. They classified the items into 6 themes that vary across Purposeful SDM modes and then into one of the four modes (weighing, negotiating, problem-solving, developing insight). Disagreements were resolved by consensus.ResultsThe items were classified as pertaining to the following themes: problem (28), roles/participation (84), options (62), preferences (21), decision (15), and evaluation (6). They were then classified as pertaining particularly to the SDM modes of weighing (54), negotiating (5), problem-solving (0), and developing insight (0) modes, with 191 items applying broadly to all modes of Purposeful SDM.ConclusionsObserver-based SDM measures describe behaviors pertinent to all modes but lack items sensitive to behaviors particular to some modes of SDM.Practice ImplicationsNew or revised observer-based measures of the SDM process could help estimate the extent to which the appropriate SDM mode is being used to address the patient’s problem.  相似文献   
7.
8.
目的 探讨带感觉功能上臂外侧嵌合骨皮瓣修复手指复合组织缺损的临床效果。方法 回顾性研究。纳入2016年11月—2019年11月徐州仁慈医院手外科收治的6例手指软组织缺损伴指骨、神经缺损患者。其中,男4例,女2例;年龄33~61岁,平均47.3岁;右手2例,左手4例;拇、示、中指各1例,环指3例;皮肤缺损面积1.0 cm×1.5 cm~2.5 cm×3.0 cm,骨缺损长度1.5~2.5 cm。6例患者均采用一期创面彻底清创,创面缺损伴指骨、神经缺损先行异种皮覆盖创面,克氏针维持骨折稳定性;二期带感觉功能的上臂外侧嵌合骨皮瓣游离移植修复治疗,皮瓣设计面积1.5 cm×2.0 cm~3.0 cm×3.5 cm,骨瓣切取大小为1.5 cm×1.0 cm×1.0 cm~3.0 cm×1.5 cm×1.0 cm。术后采用中华医学会手外科学会手部功能评定标准评价手功能,英国医学研究委员会(BMRC)制定的感觉分级方法评价皮瓣感觉恢复效果,Michigan手部功能问卷评定标准评定患指外观满意度。结果 本组6例患者手术均顺利完成,术后随访3~7个月,平均13.5个月。6例皮瓣全部成活,骨折均愈合,骨瓣平均愈合时间3~6个月,平均3.5个月。供区直接缝合,创面均一期愈合。手部功能优5例、良1例,手指感觉恢复至S4级4例、S3+级2例,患指外观满意度评价非常满意1例、满意4例、一般1例。结论 带感觉功能的上臂外侧嵌合骨皮瓣游离移植,可同时修复手指软组织缺损和指骨缺损,对供区影响小,术后手指感觉功能恢复好,是修复手指复合组织缺损的备选方案之一。  相似文献   
9.
ObjectivesThis study was conducted to compare the healing response of localized gingival recession defects treated with a coronally advanced flap (CAF) and either an amnion allograft membrane (AM) or a connective tissue graft (CTG).MethodsGingival recession defects were surgically created in six healthy mongrel dogs at the labial root surface of the maxillary canines, bilaterally. Using a split mouth design, the defects were treated with CAF and either AM (CAF/AM) or CTG (CAF/CTG). Three animals for each group were scarified at 1 and 3 months. Segments containing the defects were prepared for histological and histometric analysis.ResultsBoth techniques showed similar clinical findings with adequate root coverage. Histologically, healing was characterized by the formation of new cementum and new connective tissue attachment in the CAF/AM group; in the CAF/CTG group, healing was characterized by junctional epithelium, coronally, and connective tissue fibers parallel to the root surface, apically. Histometrically, the CAF/AM group revealed a substantially shorter epithelial length and a longer, new cementum compared with those of the CAF/CTG group after a healing period of 3 months.ConclusionsWithin the limits of this study, we concluded that the AM allograft could promote periodontal healing in gingival recession defects.  相似文献   
10.
《Australian critical care》2022,35(5):491-498
BackgroundAn activity to provide a tangible keepsake following the death of a loved one is termed ‘memory making’. However, limited evidence is available related to professionals' education and support to provide memory making opportunities in the adult intensive care unit (ICU). Having a greater understanding of healthcare professionals’ experiences can inform future patient/family care and support for professionals in end-of-life care.ObjectiveThe objective of this study was to describe what participants perceive memory making to be, if they have facilitated memory making activities as part of their practice, if they perceive it as part of their role, and if they have the necessary skills to do so.MethodsSeventy-five registered nurses (75% response rate), 19 medical doctors (76% response rate), and two social workers (66.7% response rate) completed a survey at a single tertiary referral centre in an adult ICU.ResultsParticipants reported memory making to include the creation of tangible keepsakes as well as nontangible activities. Overall, participants reported high agreement scores that the responsibility for initiating memory making predominately belonged to the nurse. Participants reported skills most needed involved the ability to interact with the family, being open to the concept, and integrating memory making into their standard of care. Having developed a rapport with families was considered an enabler, whereas lack of knowledge and clinical workload were reported as inhibitors to offering memory making.ConclusionsOverall, participants in this study reported positive experiences with offering memory making to families during end-of-life care in the adult ICU. Nurses are more likely to perceive professional responsibility for offering memory making, likely due to their increased time at the bedside and higher prominence and leadership in other end-of-life practices. To support professionals, education should include conceptual knowledge, procedural knowledge of keepsake creations, communication techniques using reflective practices, and organisational support to facilitate time requirements.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号